Contract Research Expenses (Ineligible for NY Credit)

In the regulatory environment of New York State tax incentives, contract research expenses represent payments made to third-party entities for scientific services, which are explicitly disqualified from the calculation of the Life Sciences Research and Development Tax Credit. This specific exclusion forces businesses to distinguish between their internal operational investments and their outsourced technical requirements, as only the former facilitates the high-rate refundable subsidies provided by the state.

The New York Life Sciences Research and Development Tax Credit represents a sophisticated policy instrument designed to cultivate a self-sustaining innovation ecosystem by prioritizing the localization of scientific talent and physical capital. Unlike the federal Research and Experimentation credit under Internal Revenue Code (IRC) Section 41, which typically permits a 65% inclusion of contract research payments, the New York life sciences incentive restricts its benefits to wages and supplies directly incurred by the taxpayer within the state. This deliberate policy deviation reflects the state’s strategic intent: to ensure that the $10 million annual credit pool serves as a direct catalyst for New York-based job creation rather than a pass-through subsidy for out-of-state service providers. By rendering contract research expenses ineligible, the program essentially mandates that “new businesses”—defined by their nascent status and independence from established taxpayers—must internalize their core research and development functions to qualify for the maximum fiscal relief. This distinction creates a significant bifurcated compliance landscape for biotechnology, pharmaceutical, and medical device firms, where the decision to hire a Contract Research Organization (CRO) for specialized clinical trials or toxicology reports results in a complete forfeiture of state-level tax benefits for those specific expenditures.

The Statutory Architecture of New York Life Sciences Incentives

The foundation of the Life Sciences Research and Development Tax Credit is rooted in the New York Tax Law, specifically codified to attract emerging companies in fields ranging from genomics to biopharmaceuticals. To understand the ineligibility of contract research, one must first analyze the broader legislative goals established by the Empire State Development (ESD) and the Department of Taxation and Finance (DTF).

Administrative Oversight and Legislative Intent

The program is not a traditional entitlement but a certified incentive program requiring pre-approval and ongoing performance verification. Administered by Empire State Development, the initiative seeks to bridge the gap for “new businesses” during their most capital-intensive phases. The legislative intent behind the $500,000 annual cap per firm is to distribute limited state resources across a wider array of startups, preventing a few large players from exhausting the $10 million annual statewide allocation.

The exclusion of contract research expenses is the primary mechanism through which the state enforces its “on-soil” requirement. While supplies used in research are eligible if used in New York, and wages are eligible if the employees are based in the state, the state recognizes that contract research is highly mobile. By making these costs ineligible, New York effectively prevents “innovation leakage,” where state tax dollars might otherwise subsidize a lab in another jurisdiction simply because a New York firm hired them.

Defining the “New Business” Standard

Eligibility for the credit is strictly limited to entities that qualify as a “new business” under Section 210-b(1)(f) of the Tax Law. This definition is central to the program’s integrity and prevents existing companies from restructuring or creating shell subsidiaries to claim credits. The state applies a multi-pronged test to verify this status:

Criteria	Regulatory Requirement
Ownership Control	If the applicant is a C-Corporation, less than 50% must be owned or controlled, directly or indirectly, by another New York State taxpayer.
Operational Similarity	The applicant cannot be substantially similar in ownership or operation to another entity that is or was a taxpayer in New York State.
Time in Operation	The entity must not have been a taxpayer in the state (or the individual owner must not have operated the business) for more than five years.

This “new business” requirement ensures that the Life Sciences credit remains a tool for growth and new market entry, rather than a permanent subsidy for established industries.

Technical Analysis of Contract Research Ineligibility

The core challenge for tax directors and R&D managers in New York is reconciling the state’s definitions with the familiar federal standards found in IRC Section 41. While the state adopts much of the federal language for “qualified research,” it creates a hard boundary at the point of outsourcing.

Intersection with IRC Section 41(b)

Federal law generally identifies three categories of Qualified Research Expenses (QREs): in-house wages, supplies, and contract research expenses. Under IRC Section 41(b)(3), a taxpayer can typically claim 65% of amounts paid to a third party for the performance of qualified research. In some instances involving basic research payments to universities or scientific research organizations, this rate can rise to 75% or even 100%.

New York’s Life Sciences program explicitly diverges by adopting the federal definitions for wages and supplies but categorically stating that “qualified expenditures do not include contract research expenses”. This exclusion applies regardless of where the contractor is located. Even if a New York-based startup hires a New York-based lab to perform specialized testing, the expense remains ineligible because it is a third-party contract rather than an internal payroll or supply cost.

Categorization of Ineligible Services

In the context of life sciences, many specialized services that are integral to drug or device development fall under the “contract research” umbrella and are thus disqualified for the New York credit. This includes:

• Contract Research Organizations (CROs): Payments to CROs for managing clinical trials, gathering patient data, or providing statistical analysis.
• Third-Party Laboratory Services: Fees for external toxicology, metabolic profiling, or genomic sequencing services performed by a vendor.
• Technical Consulting: Payments to independent scientific advisors or specialized engineering consultants who are not W-2 employees of the claimant.
• Outsourced Prototyping: Costs paid to external manufacturers to produce experimental models or prototypes for testing purposes.

The state’s guidance clarifies that only three categories are eligible: wages for employees performing qualified services, supplies used in the conduct of qualified research, and amounts paid for the right to use computers in the conduct of research.

Local State Revenue Office Guidance and Law Application

The New York Department of Taxation and Finance and Empire State Development provide a framework of instructions, technical memorandums (TSB-Ms), and application procedures that dictate how firms must report their R&D activities.

The Role of Empire State Development (ESD)

ESD serves as the primary gateway for the credit. A business must first be certified by ESD as a “qualified life sciences company”. This involves a Consolidated Funding Application (CFA) where the firm must demonstrate that the majority of its efforts are devoted to research, development, technology transfer, or commercialization in qualified life sciences fields.

Qualified fields under ESD guidance include:

• Agricultural Biotechnology: Research into crops, soil science, and bio-industrial processes.
• Biopharmaceuticals: Development of therapeutics, vaccines, and biologics.
• Biomedical Engineering and Medical Devices: Prototyping and engineering of medical hardware.
• Genomics and Stem Cell Research: Advanced cellular and genetic investigations.
• Neurological Clinical Trials: Specialized research into brain and nervous system disorders.

Tax Department Compliance: Forms CT-648 and IT-648

Once certified by ESD, the company claims the credit on its tax return using Form CT-648 (for C-Corps) or Form IT-648 (for partnerships, S-Corps, and individuals). The instructions for these forms are explicit regarding the exclusion of contract research.

The credit amount is determined by the size of the company’s workforce in New York:

• 20% Credit Rate: For companies with fewer than 10 full-time employees.
• 15% Credit Rate: For companies with 10 or more full-time employees.

This tiered structure creates a significant incentive for very small startups to maximize their internal spending. A startup with 8 employees can essentially receive a 20% “discount” on its entire New York research payroll, whereas if it outsourced that same work, it would receive 0% from the state.

Interpretation of “Direct and Predominant” Use

The DTF also provides guidance on the “supplies” component of the credit, which is often intertwined with contract research. Under TSB-M-19(1)S and related bulletins, property must be used “directly and predominantly” in research to qualify. “Directly” means the materials must perform the actual R&D work, while “predominantly” requires more than 50% use for research purposes.

Eligible Supply Examples	Ineligible (Administrative/Contract) Examples
Lab reagents and chemical compounds.	Office furniture and clerical desks.
Experimental prototypes consumed in testing.	Paper used for marketing reports or business decisions.
Specialized sensors and biosensors.	General-purpose transportation equipment.

This distinction is vital because firms sometimes attempt to classify contract service fees as “supplies” by arguing they are paying for a finished prototype. However, revenue guidance generally holds that if the payment is for the service of development, it is an ineligible contract research expense.

Comparative Financial Analysis: A Case Study

To demonstrate the impact of the contract research exclusion, we can analyze two hypothetical life sciences firms with different operational models. Both are “new businesses” with fewer than 10 employees, qualifying them for the 20% credit rate.

Model A: The Outsourced Firm

“BioLogic Solutions” chooses to maintain a lean internal staff of 3 people and outsources the majority of its Phase I trial work to a CRO.

Expense Category	Total Spend	NY Life Sciences Eligibility	Eligible Amount
Internal Salaries (NY)	$300,000	Eligible (Wages)	$300,000
Lab Supplies (NY)	$100,000	Eligible (Supplies)	$100,000
Contract Research (CRO)	$1,500,000	Ineligible	$0
Total Potential QREs	$1,900,000		$400,000

Total NY Credit for Model A: $400,000 x 20% = $80,000

Model B: The Internalized Firm

“NeuroTech NY” chooses to hire 9 internal researchers to perform the same Phase I work, investing in their own lab equipment and supplies.

Expense Category	Total Spend	NY Life Sciences Eligibility	Eligible Amount
Internal Salaries (NY)	$1,500,000	Eligible (Wages)	$1,500,000
Lab Supplies (NY)	$400,000	Eligible (Supplies)	$400,000
Contract Research	$0	N/A	$0
Total Potential QREs	$1,900,000		$1,900,000

Total NY Credit for Model B: $1,900,000 x 20% = $380,000 (below $500k cap) = $380,000

Economic Insight

Model B receives $300,000 more in cash refunds from New York State than Model A, despite having the same total R&D budget. This creates a powerful economic nudge to transition from 1099 contractors to W-2 employees. The $300,000 difference could potentially fund 2-3 additional junior scientist positions, further accelerating the company’s growth within the New York ecosystem.

Interplay with Other New York R&D Incentives

It is crucial for professional advisors to note that the exclusion of contract research is unique to the Life Sciences program. Other New York credits, such as the Excelsior Research and Development Tax Credit, follow different rules.

The Excelsior Research and Development Tax Credit

Housed within the Excelsior Jobs Program, this credit offers a 6% return on QREs (8% for green projects). Crucially, the Excelsior R&D credit defines QREs as the same as federal Section 41 QREs, provided the costs are incurred in New York. This means that for Excelsior participants, contract research is generally eligible, provided the research is performed within the state.

However, the Excelsior program requires a business to commit to specific job creation and investment targets. The Life Sciences credit, by contrast, has no specific job creation requirement; it simply rewards the expenses associated with whatever staff the company already has, using the employee count only to set the rate (15% vs 20%).

The Qualified Emerging Technology Company (QETC) Employment Credit

The QETC credit is another alternative, designed for companies with $10 million or less in annual product sales. It focuses on job creation and allows a credit of $1,000 per new employee. While it also uses R&D activity as an eligibility trigger (based on NSF ratios), it is a distinct mechanism from the Life Sciences expense-based credit.

Selecting the Optimal Credit Path

Businesses must evaluate which program yields the highest return. For a company with heavy contract research needs that cannot be internalized, the Excelsior program might be more beneficial despite the lower 6% rate, because 6% of a large contract-inclusive base may exceed 20% of a small wage-only base.

Audit Risks and Documentation Standards

Given that the Life Sciences credit is fully refundable—meaning the State issues a check for the excess over tax liability—it is a high-priority area for audits by the New York State Department of Taxation and Finance.

Contemporaneous Recordkeeping

To successfully defend a claim that excludes contract research, a taxpayer must maintain a “paper trail” that clearly segregates internal labor from external services. Revenue office guidance emphasizes that documents must be contemporaneous, created at the time the research was performed.

Necessary audit documentation includes:

• Detailed Payroll Records: W-2s and payroll registers for all New York employees, mapped to specific R&D projects.
• Employee Time Logs: Or a robust time-tracking system that captures the hours spent on qualified vs. non-qualified activities (e.g., administrative work vs. lab work).
• Supply Invoices: Receipts for materials used in research, with evidence that the items were used in New York.
• Contracts and Invoices from Third Parties: Even though these are ineligible, they must be maintained to prove they were properly excluded from the credit calculation during an audit.

Common Audit Pitfalls

A common mistake discovered during audits is the misclassification of “leased employees” or Professional Employment Organization (PEO) staff. While PEO employees are often treated as W-2 employees for many purposes, the state scrutinizes whether they meet the specific definition of “employees of the taxpayer” for the Life Sciences credit. If they are treated as external contractors, their costs may be disqualified.

Another pitfall involves “technical services” that do not rise to the level of experimentation. Activities such as routine quality control, seasonal research, or market studies are excluded from the federal definition of R&D and thus remain ineligible for the New York credit, regardless of whether they are performed in-house or via contract.

Strategic Business Implications of the Exclusion

The ineligibility of contract research expenses is more than a tax rule; it is a business strategy constraint that shapes how biotech and medtech firms scale in New York.

The “Make vs. Buy” Decision in R&D

Life science executives must constantly weigh the speed of outsourcing against the cost-efficiency of internalizing. Using a CRO allows a firm to access specialized expertise and equipment without the capital expenditure of building a lab. However, in New York, the “buy” decision carries an opportunity cost of up to 20% of the contract value.

For a startup with a $1 million clinical trial, the decision to “make” (hire internal staff to run the trial) vs “buy” (contract with a CRO) is a $200,000 tax decision. Over the three-year eligibility period, this can total $600,000 in lost or gained cash flow—a sum that can be the difference between a successful Series B round or insolvency.

Workforce Localization and the NYC Biotech Corridor

This policy has contributed to the clustering of life sciences firms in areas like the Long Island City biotech hub and Manhattan’s East Side. By incentivizing in-house employment, the state has fostered a concentrated market for scientific talent. This localization effect creates a feedback loop: as more firms internalize their research to capture tax credits, the pool of local talent grows, making it easier for the next firm to hire rather than outsource.

Future Outlook and Program Sustainability

The New York Life Sciences Research and Development Tax Credit is a finite program with a $10 million annual statewide cap. This cap is awarded on a first-come, first-served basis, making early application through the ESD portal essential for success.

Legislative Trends

Recent annual reports from Empire State Development indicate a high utilization of the program, with over $50 million allocated since 2018 to support the growth of the life sciences cluster. There is ongoing discussion in the state legislature regarding whether to expand the program’s cap or extend the three-year benefit window for certified firms. However, the core principle of excluding contract research remains a popular policy feature among legislators who want to ensure that tax benefits are directly linked to New York paychecks.

Impact of Global Supply Chain Shifts

As global supply chains for pharmaceuticals and medical devices face increased pressure, the state’s focus on internalizing R&D and supply chains aligns with broader national trends toward “reshoring” critical technologies. The Life Sciences credit serves as a micro-level tool to encourage firms to build “resilient” internal capabilities in New York rather than relying on global contract networks.

Final Thoughts: Navigating the Ineligibility Landscape

The New York Life Sciences Research and Development Tax Credit offers one of the most generous state-level subsidies for innovation, provided businesses adhere to its strict preference for internal investment. The categorical ineligibility of contract research expenses serves as the program’s primary gatekeeper, ensuring that the state’s fiscal support is exclusively harnessed for the development of a local workforce and the procurement of local supplies.

For life sciences firms, success under this regime requires an integrated approach to tax and operations. Business leaders must recognize that every dollar shifted from an external contractor to an internal New York-based employee carries a potential 20% premium in the form of a refundable tax credit. By carefully managing the “new business” certification process through Empire State Development and maintaining meticulous, contemporaneous records that segregate eligible wages and supplies from disqualified contract fees, companies can secure up to $1.5 million in lifetime cash flow. This funding is critical for navigating the “valley of death” between initial discovery and commercialization, ultimately allowing New York to remain a premier global destination for the life sciences industry.